• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Feasibility of Sentinel Cerebral Embolic Protection Device Deployment During Transfemoral Transcatheter Aortic Valve Replacement
Cerebral embolic protection has emerged as a preventive measure for procedural stroke in transcatheter aortic valve replacement (TAVR).1 The Sentinel System (Boston Scientific Corp. Boston, Massachusetts), a 2-filter debris-capturing system, has been the only commercially available protection device in the United States since its approval by the Food and Drug Administration in 2017. In the Sentinel trial, the largest randomized trial (n  = 363) so far, the device was successfully deployed in 94.7% of patients.
Source: The American Journal of Cardiology - October 1, 2022 Category: Cardiology Authors: Toshiaki Isogai, Husitha Reddy Vanguru, Amar Krishnaswamy, Ankit Agrawal, Nikolaos Spilias, Shashank Shekhar, Anas M. Saad, Beni Rai Verma, Rishi Puri, Grant W. Reed, Zoran B. Popovi ć, Shinya Unai, James J. Yun, Ken Uchino, Samir R. Kapadia Source Type: research

Impact of Hospital Volume on Utilization and Outcomes of Sentinel Cerebral Protection System During Transcatheter Aortic Valve Implantation
Stroke remains a serious complication of transcatheter aortic valve implantation (TAVI) with a significant impact on long-term morbidity and mortality. Although the etiology of strokes is multifactorial, most are a result of embolization of debris during the procedure.1 Multiple devices have emerged aiming to reduce the incidence of stroke through cerebral embolic protection. The Sentinel cerebral protection system (CPS) is the only Food and Drug Administration-approved device in the United States.
Source: The American Journal of Cardiology - July 13, 2022 Category: Cardiology Authors: Agam Bansal, Toshiaki Isogai, Mohamed M. Gad, Grant W. Reed, Rishi Puri, Amar Krishnaswamy, Samir R. Kapadia Source Type: research

Impact of Cerebral Embolic Protection Devices on the Incidence and Outcomes of Delirium After Transcatheter Aortic Valve Implantation
Postoperative delirium is a well-recognized complication after transcatheter aortic valve implantation (TAVI) that is associated with a significantly increased mortality and prolonged hospitalization stay.1 Ischemic brain injury has been hypothesized to be one of the predominant mechanisms responsible for delirium after TAVI. Brain injury during TAVI involves microinfarctions caused by cerebral embolization of the aortic plaque or valve particles dislodged during the prosthesis deployment.1,2 The role of cerebral embolic protection (CEP) devices has been studied in preventing stroke during TAVI.
Source: The American Journal of Cardiology - April 15, 2022 Category: Cardiology Authors: Agam Bansal, Anirudh Kumar, Grant W. Reed, Rishi Puri, Amar Krishnaswamy, Axel Linke, James Yun, Samir R. Kapadia Source Type: research

Impact of Timing of Infective Endocarditis After Transcatheter Aortic Valve Implantation on Mortality
It is well established that infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI) is associated with significantly increased mortality (1-year mortality rates as high as 50%) and stroke rates.1,2 Existing studies have determined the predictors of IE after TAVI and mortality in patients with IE after TAVI.1,2 Stortecky et al3 determined that the incidence of IE after TAVI was highest in the early procedural/periprocedural period ( ≤100 days). Similar findings were shown by Mentias et al.
Source: The American Journal of Cardiology - February 11, 2022 Category: Cardiology Authors: Agam Bansal, Anirudh Kumar, Grant W. Reed, Rishi Puri, Amar Krishnaswamy, Samir R. Kapadia Source Type: research

Prevalence of In-hospital Stroke Comparing MitraClip and Transcatheter Aortic Valve Implantation
Transcatheter aortic valve implantation (TAVI) and mitraclip (MC) are increasingly utilized for the treatment of aortic stenosis (AS) and mitral regurgitation (MR), respectively. Perioperative stroke is one of the most serious complications following TAVI given the valve calcification and possible embolization during valve implantation, and thus ongoing trials are assessing the use of embolic protection device following TAVI. On the other hand, no such trials are being conducted on MC as the evidence of stroke following MC is lacking and MC does not share the same etiology with TAVI 1.
Source: The American Journal of Cardiology - January 5, 2021 Category: Cardiology Authors: Anas M. Saad, Keerat Rai Ahuja, Omar M. Abdelfattah, Mohamed M. Gad, Toshiaki Isogai, Manpreet Kaur, Grant W. Reed, James Yun, Amar Krishnaswamy, Samir R. Kapadia Source Type: research

Benefit of Single Antiplatelet Therapy Over Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation
Current practice guidelines recommend dual antiplatelet therapy with aspirin and clopidogrel for 3-6 months followed by lifelong aspirin after transcatheter aortic valve implantation (TAVI). However, recently published POPular TAVI trial1 and other trials2 –4 that have compared dual antiplatelet therapy (DAPT) with single antiplatelet therapy (SAPT) have shown decreased bleeding events and non-inferiority with respect to ischemic stroke, all-cause mortality, and myocardial infarction (MI) amongst patients receiving SAPT.
Source: The American Journal of Cardiology - December 8, 2020 Category: Cardiology Authors: Agam Bansal, Ashish Kumar, Vardhmaan Jain, Grant W Reed, Amar Krishnaswamy, Ankur Kalra, Rishi Puri, Samir R. Kapadia Source Type: research